Back

Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients.

1 September 2024 (17:03 - 17:15)
Organised by: Logo
Congress Presentation Part of: Smaller trials: cardiac function and remodelling Cardio-Oncology ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Yuling Hsu

National Cheng Kung University Hospital, Tainan (Taiwan)

4 More presentations in this session

Presentation thumbnail
Strain sUrveillance during Chemotherapy for improving Cardiovascular Outcomes: Results of a Randomized Trial of Cardioprotection for Reduced Myocardial Strain (SUCCOUR-MRI)
Professor T. Marwick (Melbourne, AU)
Slides Video
Presentation thumbnail
Catheter Ablation versus Medical Rate Control in Atrial Fibrillation with Left Ventricular Systolic Dysfunction and Myocardial Fibrosis - The CAMERA-MRI II Randomized Trial
Associate Professor S. Prabhu (Melbourne, AU)
Slides Video
Presentation thumbnail
Sacubitril/valsartan compared to valsartan in regressing myocardial fibrosis in stage B heart failure: the REVERSE-LVH Trial
Doctor C. Chin (Singapore, SG)
Slides Video
Presentation thumbnail
Empagliflozin to prevent worsening of left ventricular volumes and systolic function after myocardial infarction
Doctor J. Carberry (Glasgow, GB)
Slides Video

Access the full session

Session thumbnail
Smaller trials: cardiac function and remodelling
Video

The Event

Event poster

ESC Congress 2024

1 September 2024 17:03 CET
You may be interested in
thumbnail
Congress Presentation
Effect of sacubitril/valsartan or enalapril on left ventricular function in patients with hematologic malignancies treated with bone marrow transplantation
thumbnail
Congress Presentation
Myocardial protection by novel treatment modalities
thumbnail
Congress Session
Smaller trials: cardiac function and remodelling

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources